目次

1. CD 47 as Novel Cancer Immunotherapy Target

2. Ongoing Anti-CD47 Agents in Clinical Trials
2.1. CD47 Targeting Monoclonal Antibodies
2.2. CD47 Targeting Bispecific Antibodies

3. Current Market Trends and Future Prospects

4. Global CD47 Inhibitors Drug Clinical Pipeline Overview
4.1. By Country
4.2. By Company
4.3. By Indication
4.4. By Phase

5. Global CD47 Inhibitors Drug Clinical Pipeline By Company, Indication and Phase
5.1. Research
5.2. Preclinical
5.3. Phase-I
5.4. Phase-I/II
5.5. Phase-II
5.6. Phase-II/III
5.7. Phase-III

6. Global CD47 Inhibitor Drug Market Dynamics
6.1. Key Factors Driving CD47 Inhibitor Clinical Trials
6.2. Clinical and Technological Challenges

7. Competitive Landscape
7.1. Adagene
7.2. Alector
7.3. ALX Oncology
7.4. Beta Pharma
7.5. Biocad
7.6. ImmuneOncia Therapeutics
7.7. ImmuneOnco Biopharma
7.8. Light Chain Bioscience
7.9. Phanes Therapeutics
7.10. Virtuoso Therapeutics

List of Figures & Tables
Figure 4-1: Global - Number of CD47 Inhibitor Drugs Clinical Trial by Country, 2022 till 2028
Figure 4-2: Global - Number of CD47 Inhibitor Drugs in Clinical Pipeline by Company, 2022 till 2028
Figure 4-3: Global - Number of CD47 Inhibitor Drugs in Clinical Pipeline by Indication, 2022 till 2028
Figure 4-4: Global - Number of CD47 Inhibitor Drugs in Clinical Pipeline by Phase, 2022 till 2028